Questions: Food-Drug Interactions and Nutrient-Medication Effects

Question 1

A patient on warfarin starts eating large daily salads with spinach and kale to improve their diet. What is the predicted effect, and what is the correct clinical management?

• A. Vitamin K will reduce anticoagulant effect; the patient should eliminate leafy greens from their diet
• B. Vitamin K will compete with warfarin's mechanism, reducing anticoagulant effect; the patient should maintain consistent vitamin K intake and adjust the warfarin dose accordingly
• C. Warfarin blocks all vitamin K pathways, so dietary vitamin K has no effect on anticoagulation
• D. Dietary vitamin K enhances warfarin's effectiveness by providing substrate for the clotting cascade

Answer: (B)

Warfarin blocks vitamin K-dependent carboxylation of clotting factors II, VII, IX, and X. Dietary vitamin K provides competing substrate, reducing anticoagulant effect. The critical clinical insight is that the guidance is *consistency*, not elimination — a stable vitamin K intake allows stable warfarin dosing. Suddenly eliminating vitamin K foods would require a higher warfarin dose; resuming them later (when the patient recovers from illness and eats normally again) would then cause INR to fall dangerously. Option A's recommendation to eliminate leafy greens represents a common misconception.

Question 2

Why can a single glass of grapefruit juice significantly raise blood levels of certain drugs such as some statins and calcium channel blockers?

• A. Grapefruit juice acidifies urine and reduces renal excretion of these drugs
• B. Grapefruit stimulates bile release, increasing absorption of all oral lipophilic medications
• C. Grapefruit juice contains furanocoumarins that irreversibly inhibit CYP3A4, reducing first-pass metabolism of the drug
• D. Grapefruit juice delays gastric emptying, extending contact time between drug and absorptive surface

Answer: (C)

Grapefruit contains furanocoumarins that irreversibly inhibit CYP3A4, an intestinal enzyme responsible for the first-pass metabolism of many drugs. When CYP3A4 is blocked, more drug passes through the intestinal wall into the bloodstream intact, raising plasma concentrations two- to five-fold. Unlike reversible inhibition, this effect persists for 24–72 hours because new enzyme must be synthesized. Options A and D describe real pharmacokinetic phenomena but not the mechanism here; option B applies to fat-soluble drugs specifically, not the grapefruit effect.

Question 3

Long-term use of proton pump inhibitors (PPIs) can impair vitamin B12 absorption by reducing the gastric acid needed to release protein-bound B12.

• T. True
• F. False

Answer: True

Gastric acid activates pepsin, which cleaves B12 from the dietary proteins it is bound to. Without adequate acid, protein-bound B12 is not released and cannot bind to intrinsic factor for absorption. Long-term PPI use is therefore associated with B12 deficiency. Notably, crystalline B12 supplements do not require acid for absorption, so supplementation remains possible — but patients on long-term PPIs with fatigue or macrocytic anemia warrant B12 assessment.

Question 4

Calcium supplements improve the absorption of tetracycline antibiotics by providing mineral ions that enhance the drug's solubility in the gut.

• T. True
• F. False

Answer: False

Calcium (along with iron and magnesium) chelates tetracyclines and fluoroquinolones, forming insoluble complexes in the gut that are never absorbed. This interaction drastically reduces antibiotic bioavailability, potentially rendering treatment ineffective. These antibiotics must be taken on an empty stomach, at least 30–60 minutes before any food or supplements containing these minerals — the opposite of what the statement claims.

Question 5

Explain why the clinical instruction for a patient taking warfarin should be 'keep vitamin K intake consistent' rather than 'avoid vitamin K foods entirely'.

Model answer: A warfarin dose is calibrated to the patient's typical vitamin K intake — the dose assumes a baseline level of competing substrate. If vitamin K is eliminated, the calibrated dose becomes too high (over-anticoagulation, bleeding risk). If vitamin K is then reintroduced (during illness recovery, for example), INR drops precipitously (clotting risk). Consistency allows a stable equilibrium: the warfarin dose offsets a predictable, steady vitamin K intake. Sudden changes in either direction destabilize INR more than a moderate, steady vitamin K level does.

This is a pharmacodynamic interaction where food and drug compete at the same physiological target. The clinical principle is management of the interaction, not elimination of the food. Understanding the mechanism (competitive substrate) explains why consistency matters more than absolute avoidance — a principle that applies to other competitive interactions as well.